<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030714</url>
  </required_header>
  <id_info>
    <org_study_id>E002</org_study_id>
    <nct_id>NCT05030714</nct_id>
  </id_info>
  <brief_title>Evaluation of a Novel Head-Mounted Device for Glaucoma Testing: A Proof-of-Concept Study</brief_title>
  <official_title>Evaluation of a Novel Head-Mounted Device for Glaucoma Testing: A Proof-of-Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brennan Eadie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study aims to determine the feasibility and effectiveness of using a&#xD;
      custom head-mounted device for visual field testing. The novel head-mounted device, with&#xD;
      custom software, will be compared to a conventional visual field test: The Humphrey Visual&#xD;
      Field Analyzer. The investigators will include 30 healthy normal patients, 30 glaucoma&#xD;
      suspects, 30 patients with moderate glaucoma, and 30 patients with advanced glaucoma (total:&#xD;
      120 patients). Each patient will perform the conventional test and the head-mounted device&#xD;
      visual field test during the study visit, with the order (i.e., which device the patient&#xD;
      starts with) being randomized. After the two tests, the patient will fill out a questionnaire&#xD;
      to gather information regarding patient comfort and satisfaction. This will repeat each week&#xD;
      for 5 weeks, for a total of 5 study visits. The results of the tests (sensitivity thresholds)&#xD;
      will be compared. The investigators hypothesize that the results of the conventional and&#xD;
      head-mounted device will be similar.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field differential light sensitivity</measure>
    <time_frame>5 weeks</time_frame>
    <description>Comparison of differential light sensitivity threshold estimated with the Humphrey Visual Field Analyzer and the custom head-mounted device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of sensitivity values</measure>
    <time_frame>5 weeks</time_frame>
    <description>Comparison of the reproducibility of sensitivity values estimated with the Humphrey Visual Field Analyzer and the custom head-mounted device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual Field Testing</intervention_name>
    <description>Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous visual field test with Humphrey Field Analyzer indicating normal field, early&#xD;
             glaucomatous field damage, moderate glaucomatous field damage, or advanced&#xD;
             glaucomatous field damage.&#xD;
&#xD;
          -  Ability to understand and consent to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of secondary glaucoma&#xD;
&#xD;
          -  Diagnosis of non-glaucomatous optic neuropathy or other significant ophthalmic&#xD;
             diagnosis that could limit vision (ex. age-related macular degeneration)&#xD;
&#xD;
          -  Significant media opacity&#xD;
&#xD;
          -  Previous intraocular surgery other than cataract surgery&#xD;
&#xD;
          -  Anxiety disorder&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Cardiac pacemaker or other implantable devices&#xD;
&#xD;
          -  Severe vertigo or balance disturbance&#xD;
&#xD;
          -  Refractive error greater than +4 diopters and less than -6 diopters spherical&#xD;
             equivalent&#xD;
&#xD;
          -  Inability to demonstrate competence to make informed decision regarding study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brennan Eadie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Healthy Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brennan Eadie, MD, PhD</last_name>
    <phone>902-292-0873</phone>
    <email>eadie.brennan.d@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Victoria General Hopsital - Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Brennan Eadie, MD, PhD</last_name>
      <phone>902-292-0873</phone>
      <email>eadie.brennan.d@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eadie Technologies Inc.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3L 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Brennan Eadie, MD, PhD</last_name>
      <phone>902-292-0873</phone>
      <email>eadie.brennan.d@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Brennan Eadie</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Ophthalmology, Dalhousie University and Nova Scotia Health Authority; MD, PhD, FRCSC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

